

Hetlioz[®] (tasimelteon) – First-time generic update

- On December 29, 2022, [Teva launched an AB-rated generic version of Vanda™—s Hetlioz \(tasimelteon\) capsules.](#)
 - Apotex received FDA-approval of an [AB-rated generic version of Hetlioz](#) on December 20, 2022. Launch plans are pending.
- Hetlioz capsules are approved for the treatment of non-24-hour sleep-wake disorder in adults, and for the treatment of nighttime sleep disturbances in Smith-Magenis Syndrome in patients 16 years of age and older.
- Teva received FDA approval of [tasimelteon](#) for the treatment of non-24-hour sleep-wake disorder in adults.